FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560388207> ?p ?o ?g. }

• W2560388207 endingPage "A101" @default.
• W2560388207 startingPage "A101.1" @default.
• W2560388207 abstract "<h3>Objective</h3> Evaluate the efficacy, safety and tolerability of deutetrabenazine for chorea in Huntington’s disease (HD). <h3>Background</h3> Deutetrabenazine (SD-809) is a novel deuterium containing VMAT2 inhibitor. When deuterium, a naturally occurring form of hydrogen, is at specific sites, in this case CYP2D6 enzymatic targets on the tetrabenazine (TBZ) molecule, it prolongs active metabolite half-lives and reduces metabolic variability, without changing target pharmacology. Deutetrabenazine achieves comparable area under the curve (AUC) with lower total daily dose and dose frequency than TBZ. <h3>Methods</h3> First-HD was a randomised, double-blind, placebo-controlled trial with 8 weeks of titration to adequate chorea control plus a 4-week maintenance. The ongoing open-label ARC-HD has 2 groups: First-HD participants now in a long-term safety study; and patients switched overnight from TBZ to an AUC-matched deutetrabenazine dose with optional dose adjustments after 1 week. <h3>Results</h3> 90 subjects (45:45) enrolled in First-HD (44% female, mean age = 53.7). The total maximal chorea (TMC) score on deutetrabenazine improved by 2.5 points (21%) over placebo from baseline to end maintenance (p < 0.0001). Significantly improved secondary endpoints were patient and clinical global impressions of change (each p = 0.002) and SF-36 physical functioning scale (p = 0.03). The deutetrabenazine group had a mean BMI gain of 0.6 (0.2) kg/m², compared with a loss in the placebo group of 0.1 (P = 0.002). Mean deutetrabenazine daily dose at end treatment was ~40 mg. Three subjects terminated early, 2 on placebo. In First-HD, the most common AEs in all subjects were irritability (deutetrabenazine 6.7% vs. placebo 13.3%), somnolence (11.1% vs. 4.4%), dry mouth (8.9% vs. 6.7%) and dizziness (4.4% vs. 8.9%). Depression, anxiety, akathisia and parkinsonism were reported at same or lower rates for deutetrabenazine vs placebo. 36 HD patients (60% male, mean age 52.4) with adequately controlled chorea on stable TBZ doses for at least 8 weeks enrolled in ARC-HD. Mean TMC change from baseline was −0.8 at both week 1 and 4. The mean TBZ dose was 41 mg; mean deutetrabenazine dose weeks 1 and 4 was 20 mg and 29 mg. 21 patients at week 8 had an improvement of −1.9 (SE 0.8) in TMC, with mean deutetrabenazine dose 33 mg. <h3>Conclusions</h3> Deutetrabenazine can effectively and safely reduce chorea in HD. Improved functional and quality of life measures suggest effective chorea treatment with good tolerability and twice-daily dosing can provide clinically meaningful benefit. HD patients can safely and rapidly convert from TBZ to open-label deutetrabenazine." @default.
• W2560388207 created "2016-12-16" @default.
• W2560388207 creator A5082724740 @default.
• W2560388207 date "2016-09-01" @default.
• W2560388207 modified "2023-09-25" @default.
• W2560388207 title "M1 Deutetrabenazine: update on first time use of SD-809 in huntington’s disease (First-HD) and alternative for reducing chorea in huntington’s disease (ARC-HD)" @default.
• W2560388207 doi "https://doi.org/10.1136/jnnp-2016-314597.286" @default.
• W2560388207 hasPublicationYear "2016" @default.
• W2560388207 type Work @default.
• W2560388207 sameAs 2560388207 @default.
• W2560388207 citedByCount "0" @default.
• W2560388207 crossrefType "journal-article" @default.
• W2560388207 hasAuthorship W2560388207A5082724740 @default.
• W2560388207 hasBestOaLocation W25603882071 @default.
• W2560388207 hasConcept C126322002 @default.
• W2560388207 hasConcept C142724271 @default.
• W2560388207 hasConcept C197934379 @default.
• W2560388207 hasConcept C204787440 @default.
• W2560388207 hasConcept C27081682 @default.
• W2560388207 hasConcept C2778375690 @default.
• W2560388207 hasConcept C2778868616 @default.
• W2560388207 hasConcept C2779134260 @default.
• W2560388207 hasConcept C2780647506 @default.
• W2560388207 hasConcept C2991744798 @default.
• W2560388207 hasConcept C71924100 @default.
• W2560388207 hasConceptScore W2560388207C126322002 @default.
• W2560388207 hasConceptScore W2560388207C142724271 @default.
• W2560388207 hasConceptScore W2560388207C197934379 @default.
• W2560388207 hasConceptScore W2560388207C204787440 @default.
• W2560388207 hasConceptScore W2560388207C27081682 @default.
• W2560388207 hasConceptScore W2560388207C2778375690 @default.
• W2560388207 hasConceptScore W2560388207C2778868616 @default.
• W2560388207 hasConceptScore W2560388207C2779134260 @default.
• W2560388207 hasConceptScore W2560388207C2780647506 @default.
• W2560388207 hasConceptScore W2560388207C2991744798 @default.
• W2560388207 hasConceptScore W2560388207C71924100 @default.
• W2560388207 hasIssue "Suppl 1" @default.
• W2560388207 hasLocation W25603882071 @default.
• W2560388207 hasOpenAccess W2560388207 @default.
• W2560388207 hasPrimaryLocation W25603882071 @default.
• W2560388207 hasRelatedWork W167780674 @default.
• W2560388207 hasRelatedWork W1738773654 @default.
• W2560388207 hasRelatedWork W1966123646 @default.
• W2560388207 hasRelatedWork W1995615629 @default.
• W2560388207 hasRelatedWork W2030725658 @default.
• W2560388207 hasRelatedWork W2072113194 @default.
• W2560388207 hasRelatedWork W2871160880 @default.
• W2560388207 hasRelatedWork W4200246449 @default.
• W2560388207 hasRelatedWork W4237633959 @default.
• W2560388207 hasRelatedWork W4367296336 @default.
• W2560388207 hasVolume "87" @default.
• W2560388207 isParatext "false" @default.
• W2560388207 isRetracted "false" @default.
• W2560388207 magId "2560388207" @default.
• W2560388207 workType "article" @default.